Allurion Technologies, Inc.
- ALUR · OTC
- Surgical & Medical Instruments & Apparatus
- Natick, MA
- 41 employees
- CIK 0001964979
Updated from SEC filings through
Top things to know
Executives
- Shantanu Gaur Chief Executive Officer and President (Principal Executive Officer and Principal Financial Officer) 10-Q, 2026-05-15
- Ojas Buch Chief Operating Officer 8-K, 2026-07-23
- Brendan M. Gibbons Chief Legal Officer 5, 2026-02-17
- Brendan Gibbons Chief Legal and People Officer DEF 14A, 2025-11-24
What leadership is saying
“We are pleased with our results from the fourth quarter, where we grew revenue meaningfully quarter-over-quarter for the first time in more than one year as our new commercial strategy implemented after our strategic pivot in 2025 began to take hold”
Earnings press release (8-K Ex. 99.1), filed January 12, 2026
Allurion Technologies, Inc. is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Natick, MA. It trades as ALUR on OTC. Revenue was $15.2M in the fiscal year ending December 31, 2025, -52.6% from the year before. It reported about 41 employees. Shantanu Gaur is Chief Executive Officer and President (Principal Executive Officer and Principal Financial Officer).
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $15.2M 10-K, 2026-03-30 | $32.1M 10-K, 2026-03-30 | $53.5M 10-K/A, 2025-08-28 | $64.2M 10-K/A, 2025-08-28 |
| Operating income | -$30.2M 10-K, 2026-03-30 | -$50.2M 10-K, 2026-03-30 | -$79.1M 10-K/A, 2025-08-28 | -$32.0M 10-K/A, 2025-08-28 |
| SG&A | $32.2M 10-K, 2026-03-30 | $54.3M 10-K, 2026-03-30 | $92.9M 10-K/A, 2025-08-28 | $65.8M 10-K/A, 2025-08-28 |
| Net income | -$28.8M 10-K, 2026-03-30 | -$7.2M 10-K, 2026-03-30 | -$82.8M 10-K/A, 2025-08-28 | -$37.7M 10-K/A, 2025-08-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Shantanu Gaur | Chief Executive Officer and President (Principal Executive Officer and Principal Financial Officer) | 10-Q, 2026-05-15 |
| Ojas Buch | Chief Operating Officer | 8-K, 2026-07-23 |
| Brendan M. Gibbons | Chief Legal Officer | 5, 2026-02-17 |
| Brendan Gibbons | Named in proxy bio: Chief Legal and People Officer | DEF 14A, 2025-11-24 |
| Keith Johns | Director | 10-K, 2026-03-30 |
| Nicholas Lewin | Director | 10-K, 2026-03-30 |
What Allurion Technologies, Inc. does
Our company is pioneering metabolically healthy weight loss by creating a best-in-class weight loss platform to treat the estimated two billion people globally who are overweight. Our platform, the Allurion Program (the "Allurion Program"), features the world’s first and only swallowable, ProcedurelessTM intragastric balloon for weight loss (the "Allurion Smart Capsule") and offers access to artificial intelligence ("AI")-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging and video telehealth that make up the Allurion Virtual Care Suite (“VCS”).
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 15.0 million (as of May 12, 2026) | 10-Q, May 15, 2026 |
|---|---|---|
| Public float | $20.7M (as of June 30, 2025) | 10-K, March 30, 2026 |
| Latest proxy statement | Meeting December 18, 2025 (filed November 24, 2025) | DEF 14A, November 24, 2025 |
| Auditor | Deloitte & Touche LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| December 4, 2025 | Michael R. Davin Director | Sale | 3,212 | $5K | Form 4, December 5, 2025 |
Recent 8-K events
- 8-K filed 2026-08-24
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-07-24
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2026-07-23
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-07-07
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-30
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-17
- Item 3.03 Material modification to rights of security holders
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 8.01 Other events
- 8-K filed 2026-05-27
- Item 4.01 Changes in registrant's certifying accountant
- 8-K filed 2026-03-12
- Item 3.01 Notice of delisting or failure to meet listing standards
- Item 8.01 Other events
- 8-K filed 2026-03-02
- Item 3.01 Notice of delisting or failure to meet listing standards
- Item 8.01 Other events
- 8-K filed 2026-02-25
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 3.03 Material modification to rights of security holders
Frequently asked questions about Allurion Technologies, Inc.
- What does Allurion Technologies, Inc. do?
- In its own words, from Item 1 of its 10-K: "Our company is pioneering metabolically healthy weight loss by creating a best-in-class weight loss platform to treat the estimated two billion people globally who are overweight. Our platform, the Allurion Program (the "Allurion Program"), features the world’s first and only swallowable, ProcedurelessTM intragastric balloon for weight loss (the "Allurion Smart Capsule") and offers access to artificial intelligence ("AI")-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging and video telehealth that make up the Allurion Virtual Care Suite (“VCS”)."
- What is Allurion Technologies, Inc.'s revenue?
- $15.2M for the fiscal year ending December 31, 2025, from its 10-K filed March 30, 2026.
- Is Allurion Technologies, Inc. profitable?
- Allurion Technologies, Inc. reported net income of -$28.8M for the fiscal year ending December 31, 2025.
- How many employees does Allurion Technologies, Inc. have?
- About 41 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Allurion Technologies, Inc.?
- Shantanu Gaur, Chief Executive Officer and President (Principal Executive Officer and Principal Financial Officer), as named in a 10-Q filed May 15, 2026.
- Where is Allurion Technologies, Inc. headquartered?
- Natick, MA.
- What is Allurion Technologies, Inc.'s stock ticker?
- ALUR on OTC.
- What industry is Allurion Technologies, Inc. in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Allurion Technologies, Inc.'s website?
- allurion.com.
- When does Allurion Technologies, Inc. report earnings next?
- January 11, 2027. Source: estimate_8k_pattern.
- Is Allurion Technologies, Inc. a public company?
- Yes. Allurion Technologies, Inc. files with the SEC under CIK 0001964979 and trades as ALUR.
- Who audits Allurion Technologies, Inc.?
- Deloitte & Touche LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Allurion Technologies, Inc. are outstanding?
- 15.0 million shares as of May 12, 2026, from its 10-Q filed May 15, 2026.
- What is Allurion Technologies, Inc.'s public float?
- $20.7M as of June 30, 2025, as reported on the cover of its 10-K filed March 30, 2026.
- When is Allurion Technologies, Inc.'s annual shareholder meeting?
- December 18, 2025, per its proxy statement (DEF 14A) filed November 24, 2025.
- Have Allurion Technologies, Inc. insiders traded stock recently?
- Since December 4, 2025, officers and directors reported 1 open-market sale worth about $5K and 0 purchases on Forms 4 and 5. The most recent: Michael R. Davin (Director) sold 3,212 shares on December 4, 2025.